ABOS - Earnings call transcript Q2 2022 | Acumen Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day. Thank you for standing by, and welcome to the Acumen Pharmaceuticals, Second Quarter 2022 Update Call. At this time, all participants are in a listen-only mode. There'll be a brief overview followed by a question-and-answer session. [Operator Instructions] Today's call is being recorded. like Westwicke. the now John over would from Woolford I to call turn to And ahead. go Please

John Woolford

Thank you, update afternoon. review and operator good results. Acumen’s today joining financial second to us quarter XXXX on progress Thank operational you for

call, read statements securities section. Before financial laws, and operational during Please afternoon, is note results you materially website federal within our cause statements concerning All the statements forward-looking conference outlook the this and meaning to to accessible issued from that could including our the on financial in we the uncertainties statements. we release expected these differ in encourage of forward-looking start, described actual results that which plans. we business may those to risks are make press the subject today's and Investors

sanctions, the such could Our materially Ukraine, refer filings with effects and events factors, business. Russia financial conflict associated a including of recent and to full our and number the between markets. with extent to such inflation COVID-XX of macroeconomic due the and uncertainties uncertain as for pandemic, of geopolitical duration the of actual the Please a the results our review as related differ risks conditions, SEC credit risking and

Officer an the call INTERCEPT-AD then Eric the Alzheimer's discuss quarter and the any statements. today's disease forward-looking begin in Forward-looking made statements with Siemers, Chief and update of Daniel obligation revise business will ongoing or speak O'Connell, only review they a recent date Executive are which Chief no select Officer on on will second update provide Medical as and Acumen to President undertakes XXXX trial. Dr. development highlights. field

Business Officer brief Finally, and provide Officer Zuga, a Matt Financial will Chief update. financial Chief

hand over Officer. the will open Dan now President and Q&A. Executive the call to Dan? Chief O'Connell, call then I'll We for

Daniel O'Connell

quarter and our enter and INTERCEPT-AD monoclonal from today. to be Picking update. to the provide momentum call we generated second up to Good I'm in thank of everyone first XXXX, a selectively to early trial developed a-beta the clinical John. here make progress you, target review oligomers soluble clinic. ACUXXX, delighted to with afternoon business the continue our Thank to you joining the antibody

activation to trial INTERCEPT-AD in reported first enrollment continuing activate XX enrollment, conference XX as we at site sites now quarter sites, Regarding ongoing are clinical up May. sites. call new is active in active from our

our design trial, we to study continued in half in remain Given formulation line ongoing, trial FDA product we in to are toxicity underway. ACUXXX, INTERCEPT-AD future GLP X/X the results and on should first progress near report Phase process conducting also substance we term. the for the and production X the have with made believe of end parallel an X/X In expect The XXXX. trial, top planning study the for chronic of progress Phase we track Phase and be new drug of is in finalized meeting drug our the preparing

of to proof the they Our next INTERCEPT-AD are Phase after assuming results ongoing initiate trial potential to of mechanism. plan demonstrate the X/X is trial the prepared and available trial be of

in continues on I is economical and Prevail timely a Acumen Dr. senior is consultant leading matters. Since Lonza confident over Chief have with drug CMC, late-phase I who Sevigny, to our Program in as subsidiary over been process experience potential Medical pharmaceutical Liean of CMC has As at products commercial additions position. to delivery to Therapeutics, Board we departure Company. and Lilly support Liean industry to Board the imperative closely the recently Head than off connections Eli key with of contributor. XX Acumen Management development, years. product On XX Jeff Eli CMC Biologics who Kent CMC strategic for by Lilly she senior started for Officer of Novavax. spending for XXXX, CMC and Jeff in Jeff various want acknowledge in & different at front. a as and of we last & He and a organization last current joined more thank our most of Ensuring stepped as was which years employer. efforts on abilities and of owned continue CMC recently, recently make major are became recent position, three in to our will has management. Most a career of serve Head at of during to development Company biologics roles. VP, his years been grow a colleagues Jeff highlighted her her as and her the three the CMC our for she want missed. we before leadership his In Liean responsible working manufacturing call, these brings be project Liean XXXX appointed clinical note, wholly positions. Acumen Acumen's Schenck Iverson, served has this required I the service do

Nomination Corporate Committee Director. search Our for and potential Governance a a initiated has new

disease AAIC anticipated for Alzheimer's and data of the including soluble the to over amyloid-beta AAIC, quarters, of for upcoming in many San from assay oligomers binding gauge gantenerumab potential in research you there attended for novel donanemab. readouts evaluating and the weeks Diego. monoclonal discuss now to poster and served Eric? coming standardized On meeting a informative As versus antibodies. I'll regulatory The know, in or some clinical to field. AD properties bapineuzumab are programs as others our ago, on the the a Acumen Lilly’s developments including the that III Two of [indiscernible] recent note, meeting event latest an Phase Eric these number developments turn call developments

Eric Siemers

and Dan to afternoon Thanks good everyone.

Alzheimer's that immunotherapeutic as poised the disease. outlined in as well article extensive an for ACUXXX oligomers amyloid evidence preclinical differentiated ACUXX hypothesis April and the to First, and selectivity targeting I late oligomer to in to published Frontier's review Neuroscience that test profile. The Alzheimer's a soluble highlight is wanted and rationale beta characterize disease, amyloid of early entitled article beta

We the broad and that have and one it's the prevention we of disease. promising Alzheimer's to of toxic reduces Aβ consensus most the most progression development for that a emerging treatment form of scientific of are potential the oligomers what of oligomers, a observed be believe toxicity the and product the that of approaches

found older suggest the called mediated oligomers neurons Aβ toxicity and detailed cells publication, interact with brain neurons in and memory multiple for as each as that been specifically directly As problems. the other, more synapses function. communicate well responsible Aβ neuronal leading that neurodegeneration neuronal is Alzheimer's cognitive associated oligomer with to to studies allow to have with

Additionally, Aβ of in presented San process a Diego, detailing oligomers ADDLs. method poster ligands meeting properties initiate Acumen leading perpetuate to neurodegeneration, ultimately cell to to and AIC diffusable binding recent or assess derived appear a death. amyloid antibody designed the the At using

of characterize field and has may experiments used development could the the ADDLs these to of as that advance executed. potential you ADDLs the method by of of other the to leading ACUXXX. the were eventual antigen in description monoclonal how As properties be described recall, believe antibodies a ACUXXX the detailed binding to consistently providing We use

other time the anticipated the In broadly, in from research in field particularly near-term of addition, given readouts AD we the also an is expected field. believe data exciting companies that this

that target or selective antibodies. different We to antibodies As or hypothesized unique a less differentiated and monoclonal in are that such anti- improved other Alzheimer's or oligomers quick monoclonal selectivity amyloid plaques deposited given from studied disease, lead as Aβ selectivity Aβ reminder, ACUXXX Aβ for compared clinical other anti-amyloid antibodies efficacy the amyloid other may Aβ to monomers. high is species to its monoclonal relative

is Importantly, cognitive expect are which addition disease in a Based animals, other ARIA concerns, we with laboratory in treatment. of several believe the lack we potential on possible for ACUXXX to with data seen improvement monoclonal slowing safety antibodies. related there

line the next from INTERCEPT-AD Given the to half and top differentiation, forward first we strong data rationale in of reporting year. look

XX including INTERCEPT-AD placebo. milligrams per cohorts per in patients trial ascending XX dose administrations single ACUXXX, of kilogram at per per every cohort of drug design includes and kilogram development, dose three X, XX, dosed reminder portion kilogram or a weeks trial is placebo. ascending given XX The The eight XX Phase be or multiple ascending a portion. milligrams randomized at kilogram and with to As and doses common XX four per portions single are two ascending dose two portion and doses dose dosed for cohort milligrams three four as patients Xa/b per cohorts multiple placebo-controlled with portion every a includes weeks milligrams XX of as the

fluid. is and well of as amyloid the amount for evaluation cohort is be pathology. assuming that data potential the is expected objective trial safety Other in tolerability with those provide objectives important to our to Included to of that conducted first A cognitive measures oligomers trial of the cohorts, these early or as with portion. determined The To frequently engagement single and include as be ascending of is are cohort participate be scans. a as in given the expect the mild dementia which in The test determined to what must the is other placebo, demonstrate regulatory will target to now and words, dose patients patients crucial disease. design bound being pooled of due the Alzheimer's demonstrating of significant positive positive trial each cerebrospinal mild the mechanism pharmacokinetics trial, in X/X strategy. trial of to In two of our For ascending data be ACUXXX tolerability, trial by in second termed multiple in the patients key safety Phase ability impairment will cognition. dose is Alzheimer's portion, initiate of and the proof by design analysis. we

advance central tolerability acceptable safety and confirmed, the Chief compartment and Financial ACUXXX over we that, assuming Phase into a the target Assuming X/X INTERCEPT-AD program study. Officer Zuga, demonstrates Matt With is to profile that engagement I our that to enters Business plan Chief and Officer. and call turn the will an

Matt Zuga

are Eric, and and well the development clinical believe and have milestones. on resources everyone emphasize our joining we and as financing call. XXXX of strategy a planning capitalized thanks the to executing we result I multiple XXXX, to achieve to and for start, you, that Thank To public in private want

cash marketable securities XX, hand. million As of approximately we had and $XXX June in on

our on XXXX. Looking current expect we runway ahead, operating through last our to based plan, cash

financings Our strong XXXX. and of B proceeds IPO balance sheet is in completed the the from result Series

ongoing over XXXX want and period the period. of $XX.X we going loss and due of quarter, B year that prior quarter file fair expense quarter. to quarter cost million the $XX.X to million expect the The highlight year compared our activity $XX.X primarily and the our in to loss to increased shortly. the afternoon increase expenses Our represented complete do value was to release second the our liability our Note million results a $XX.X the tranche primarily second at prior expenses in subsequently comprehensive financial in $X.X the of company. public changes recorded for a the The G&A review of Both A-X shares to were were in as of that of quarter, extinguished end of over detail, Series million results warrant driven prior liability and headcount items. increased by in year not non-cash XXXX. period available on and million which primarily few in by in conversion result I'm the were being the common liability. the to compared balance re-measured was Series QX reporting in trial XXXX initially This led the approximately INTERCEPT-AD at value warrant to the we a quarter. at R&D period. were the with $X.X a was a XX-Q, are but this million fair loss shares and each tranche in are issued Acumen's second at our operations press the preferred in fair the liability in of The IPO. warrants sheet increase the our liability public and the from liabilities I value going second for

in quarters look data half INTERCEPT-AD over to will to the top forward We enroll line work of coming to hard reporting and XXXX. the first continue

our floor thank Importantly, for we and efficiently operate support. shareholders we'll We continue to will effectively. Acumen their And trust and partners for open questions. and cost up now ongoing the

Operator

Suisse. line you. Our Thank with comes [Operator Judah Credit Frommer question from Instructions] first the of

Your open. line is

Judah Frommer

Hi, afternoon. taking the guys. questions. for Thanks Good

us. for couple a Just

potentially. hoping And going that that on just might of on XXXX It sounds for might to was Any maybe, maybe abetamabs could with study. I best assumptions and start why a we're Phase like any cash underlying term. Matt, of kind across contemplates can what to First, middle through XXXX X/X size you late-stage of that thoughts us of help provide be? readouts the and read then maybe runway XXX you. Thank which the have near that

Matt Zuga

So of that take second back the part question, the why then don't I first. Dan come let I'll and to

Daniel O'Connell

Sure.

I think Dahan. Judah. Good question. Thanks,

and think these don't these different ACUXXX, directly anticipate a is developed purpose results was to through the products methodology. principally on any seat because I everybody late-stage ACUXXX of how their of play with We edge through out. different being see a to

the from is I think ESI's out. probably data lecanemab you different the think donanemab look one maybe those to XXX. I September. QX, products, and yet sort most got for of And looking then If at comparable And we'll that's would respectively. at be distinctly QX next read and it gantenerumab think And say that I I

So that's at helpful a large. we're some positive what to And development throughs on read for will terms XXX. success that and report in be the to generally patients really We I in hopeful relevance and beyond can't space. suggested field the I've comment think for of there

Judah Frommer

Okay.

Matt Zuga

back cash just then And question, to Judah. your

from study, a spend we XXXX way we to the the look go with reported the the FDA that design the is time on need cetera. final the So X would we still even would et of earliest study agree after at we've that data start because beginning and Phase INTERCEPT-AD,

don't study beginning That's until the start patients. pretty we as So a we'd think of XXXX. about big designed, XXX

all all with run we setting study. into our Phase the start X about X/X talked interim it this that flipped Phase could study. to X, up we a so to going have do past, of we're in Phase is we've But that's as look shareholders a Now as we're potentially an this if a

Daniel O'Connell

Do Matt's we audio. loosen

Matt Zuga

not you Can hear Dan? me

Daniel O'Connell

Now I can.

Matt Zuga

any sorry. Judah, response? hear you did I'm of that

Judah Frommer

Yeah.

-- lost started Phase I you a we think as X.

Matt Zuga

Right.

So question be study Phase to patients. The does sense a it goal it we interim when we X do being look, started as Phase X. will the an with make XXX a roll into

so would and that way at we And And into meeting so Phase then XXXX. speak. would the certainly the analysis to is in interim be the we look well it study we XXXX X do prior to finance,

Judah Frommer

a Okay. helpful. question follow-up on we And response That's really Dan's get. to just maybe then

these Just run or in in think to for kind being of presumably, you administered do late-stage the going mechanistic X potential the X/X. drugs about mabs, combo how not combo together? potentially arm ACUXXX with But any Phase a of you're these Phase

Daniel O'Connell

approach. and in patient I think will we management I is probably question think the that combination treatment and way So best Joe, the to in responded means of the potentially the multi-mechanistic that future approaches, involve it's

So I Aβ think playing the is space out.

the β as think on measured I on late-stage have plaque. primary effect assets plaques a amyloid the

selective be think tau and future. target something a Whether plaque with oligomers. the is explored you towards another that would you whether oligomers future, oligomers in Aβ whether that and target possibility soluble you an a is I mechanism XXX as may -- has is we agent something think the or also antibody in inflammatory target a positioned

this safety in sort future safety X/X to again, of and combination and initial might I engagement, think So and offer right we patient strategies for possibilities now, PK the important the -- the INTERCEPT-AD mechanism up, that of us increased think, Phase is proof benefit. demonstrate the potential of does the established target for thing and the set us study, profile that,

Judah Frommer

Great. you. Thank

Operator

you. Thank

Bank Geoff comes with Meacham question America. of next line of from Our the

is line open. now Your

Unidentified Analyst

is Thank in for the afternoon. Geoff calling question. [ph] much very for Hao Good This you Meacham.

think my said going concentration binding So be I XXX really question X to antibody Phase the it study, you oligomers, the test you're is tested. so for of the will to

And sensitive in to to give about good is therapeutic how human be you. that what wanted bounding test? sense of Just may that transferred level you Thank testing. little of bit think effect a

Eric Siemers

Yes, this is Eric.

that can I think I one. take

of look this the antibody at we'll is down So concentration at which refined oligomers. to the assay, point, being the

by So in words, target other engagement. really, definition,

safety, in long monoclonals more off you be, engagement so as show that target and as be more actually that drug strict you safety, no target we've assuming But target can better. will will the cut-off. For determined most continue engagement engagement. better have see have, the development general, number the good you there's We to need that some to we

to a we question you more better hopefully, as the target there as But again, is have your number we cut-off, need to firm it's little determined So long engagement isn't that bit, answer show there. that safety, a that

Unidentified Analyst

the about the of how sensitivity test And

Eric Siemers

right terms Well, in see concentrations I olicmers based right that based spinal fluid the We're a in our laboratory of number sufficient that we can't what cord. of spinal to on projections made, now, we'll able show drug give PK, think be concentrations sensitivity expect the we you on now in studies at trial. to some in versus of

the working Now, to more may assay. sensitive we're be need in. have up pick that to the we so the where we assay make point the the current way, we methods might And doses we with that we by But developed the to than on like measurement won't even this feel at the able do even study assay now. we actually make can certainly to lower until

give we even have sensitivity you either months on the sufficient need have even would that right mass assay animal to and be but that exploratory method, actually currently has method an to more spec exploratory the even different we other the we potential that data, increase or use be working by will a before run has and assay. we be sensitivity, like the methods some need better are to actually approach. more this. But So the an that run some laboratory more this to we the now, data would on the expect But of sensitivity based sensitivity, time in we

Unidentified Analyst

you Thank Great. so Awesome. much.

Operator

you. Thank

Our Matteis from line question Stifel. of the comes Paul next from

Your now line open. is

Unidentified Analyst

you but taken for James you continued Paul. And the into just Phase are forward the there kind data? of on a of so you outside any any enroll, of to share you as have the Maybe help dose that dose there thinking is about of kind other are you signals dose look as is to to multiple, safety some, X/X of two, then, going I know can you one couple trying look Thanks you've Thanks assay, of One, – guess, that to, This any far? Hi. just much. already been again, blended of kind sort there is us taking confidence or our forward, I taking taking the around you're for of trials guys guess, the and I quick give you're it data – right to guys have so ones. addressed that taking question. just at can seen a any color decision forward? points understand criteria remind

Daniel O'Connell

do yeah? Eric, comment that, to you on want

Eric Siemers

Yeah. Sure.

So, one advance course. extensive a we actually is pretty as that, to various the the of blinded, cohorts cohort, review each out of at safety end we point thing just through do

that. yeah, the advancing And just the been So for we looking part at have that's through criteria of study.

that – be well. cohort, the is, would results at elected, real But very far carefully going specific tell the We so don't to going appropriate. data is you think we the we're think while for safety so what that, And I look I disclose study we've is study good Now, each ongoing. can not

Daniel O'Connell

will Is the with level I we two coming of launching Phase which And out on arms. determined X/X, think study. do the be correct, the INTERCEPT-AD that anticipate of dosing Eric? dose The X Phase

Eric Siemers

Yeah, right.

and two three one active placebo, total So so arms.

Daniel O'Connell

Correct.

Eric Siemers

two for we but depend X/X, what And the on that's right on is arms that will with three depending us. the that, interim show do in see we're study, and what of we one of least envisioning results Phase now a start the active of the that we course, possible would total it's at one the Phase placebo. But to drop what we're least X with arms when planning data the at

Unidentified Analyst

Great. so Thank much. you

Operator

Thank you.

BTIG. Tom comes question the line of next Our with Shrader from

Your open. line is now

Tom Shrader

attractive XXX. formulation to? for of need I I Thanks concentration taking But mean, you think afternoon. for it's is if is for the do Good And a an sense one what have reason. companies it the doing have other you subcu overall? Cmax attractive How questions. a Do route don't get questions. some it of safety? probably you you is friendly could it

Eric Siemers

Yeah.

follow-up, I can you and that, to maybe too. want Dan, take might So

feasible as enter about before enough X, say, you know not let's the subcu. know So to enter don't you X, or it's whether Phase you well Phase pharmacokinetics go really to

this we So in will IV be study. first

assumptions and month important of terms I'm as lot clinic. that that's which versus a a the immediately dose is Phase of once we in if the I but that much we've too that Now many advantage But -- at X/X, know of at that had, change that the infusion a sure that with, it not subcu IV an make lot a out people line. of as certainly, look become I at would that is think required low least a turns don't would over-index. do down And a don't discussions, you would profitability, enough actually, it's that to for start we

it’s actively less that. be up The because [ph] with way we'll can So brought good think REA they for up the subcu that's one you looking other tied But now, was IV. the its thing, at right that that get tracking that. they point

see our in REA. expect to don't So we case,

going And think don't with we're so issue. AUC have versus to to the I deal Cmax

deal But REA we at issue won't I seen an have what based us on there's good there's far, we've so show. we'll be to that least Cmax to reason the so issue. and versus see so think and And what wait data won't for -- that with think AUC

Daniel O'Connell

we've of earnings our was just Schenck announced as on follow-up Tom, to note that. our will I release, designated CMC. that VP Eric, in as And And Liean just

of opportunities we of you types if out are formulation for wrote manufacturing, of way product us map, very part much the kind the up -- future map road So will.

obvious And see but need so move on right information the now. immediate we don't based to we're subcu a an have to paying formulation attention,

Tom Shrader

Eric approach follow-up, do is toxic effort particles? they How And -- isolated of do you if understand big stuff And is for nerdy preparation? they in-vivo a so ask why one how human isolated more I that are assay? ADDLs? this toxic brains can toxic. much your your the from Is area Are

Eric Siemers

great and Well, it's fair amount no, it's a question, one we've talked recently. about a

we used studies very the create are So that to we know ACUXXX, adult on that based those antibody to the preparation was know that various toxic neurons.

Alzheimer's of terms of more humans bit brain those actually actually experiments. it's between little in that a adults In what are the about in and see the you human brain. the difficult comparison recently And disease, just talking Alzheimer’s the do been to with

those So, under discussion. it's are but little a and bit experiments question a it's good to do, that are difficult

Tom Shrader

you. Thank Great.

Operator

you. Thank

with line comes question Bristow next from Colin of the Our UBS.

is open. line Your now

Ting Liu

Hi, good afternoon. This for Colin. Ting is Liu

potential INTERCEPT-AD, about questions the discussed the The have have we in looking upcoming we readout. blood is that So, be at the before flow. one increase you'll thing

provide flow in you in the or cerebral And follow-up blood it detecting the could questions. you. you'll So, Thank is we color more increase the have two be flow brain? the blood here

Daniel O'Connell

blood question. start off with flow maybe the I'll So

that field blood that spin and sort in changes in to or of for has that there's cerebral look who others MRI a, sequence called the do an -- a be you might but ASL fairly the is what arterial in having ARIA actually for So can It's primarily used called just patients at recently. enables look in and are MRI be flow. study, as scans what's pulse the labeling -- the familiar with study also advanced done not rapidly to

So, goes sort brain. that this blood of flow is a amount total of to the

worse research in there's get showing and long decreased that a decrease there's disease, flow with patients So, with disease Alzheimer's that blood continues Alzheimer's in progression. history of to

of So, it's really part disease. the

is So, in immediate the see and which might flow. cerebral or you we that some more will -- an happen. ACUXXX, we see But this that don't blood of if possible, increase one be improvement would effects if effects know

have that one but these we And patients in even do sequence more can so give a effects MRIs these some Phase was Xb really, of thought the us flow get if and need anyway, immediate the information study. blood this have on to of see ACUXXX, let's

Ting Liu

helpful. really And That's a separate you. have we Thank question.

computerized a We're mentioned assets which for over So, can cognitive test? you details test, you also be say, patients, will this just wondering, daily INTERCEPT-AD. the used more there's self-testing or about provide

Daniel O'Connell

Yes, sure.

first to we company a small one work been actually, do time, a of They who testing. for So, with cognitive were computerized involved long cog State, has in called the companies actually that.

computerized study, testing will I doing all clinic in that to one their there's think is home, cognitive people testing a of asking the not about question at in the be the less variability there multiple in the ongoing you then now in be sort this in the computerized that single, actually days, just in portion going the doing portion the be might in it of SAD this be but advantages hospital of disease. things traditional one those with like the lot the can Alzheimer's it over research of should done on We're computer testing briefly Internet. for you do scales a are times, is couple ADAS-cog of in patients say, of

the and battery, with it's about should some we small, almost immediate the I up, ones of scales up thing, to you it's that it you this relatively scales. just if heard drug computerized an impossible think, again, gives it but those gives and the the be traditional the if again, to that a or not But do signal to pick of that in pick a happen. should CDR a effect all this with But the so up to, us immediate immediate before. effect sure is potential will opportunity ADAS-cog study, And there pick drug the

Ting Liu

Thank a we follow-up you. have And question.

to So XX. lower then ClinicalTrials.gov XX of of XX is score recent on enrollment in change one your minor MMSE criteria, update, you XX it to the you and the to which made

you could this rationale provide change? you. what's So the Thank for more details

Daniel O'Connell

good very a That's Yes. question.

studies. really it But have mild clinician's mean, lower from thought this, it other again, screen Alzheimer's population There's consists we we MCI I to little exclude had have dementia. are with study to or bit due cutoff. to more I our somewhat as dementia. started is Exactly it's studies, MCI these enroll really it's Alzheimer's dementia. different that's study certain some them had is, based reason some study. study, we there disease experience did arbitrary have because mild XX or that was got amyloid think to see -- these were and calling people you’ll appropriate XXXX a cutoffs in people this people was appropriate all didn't just where actually really mild with got what and to scan, people of dementia. a exclude cutoff minimum cutoff people moderate is used but our a the trial, to a of for seem in the as from it disease, which people As our that positive PET early just really But dementia mean even we after used with basically. to And them different on the in people XXXX experience mild we no mild that say, between view

Ting Liu

That's really helpful. Thank you.

Operator

call remarks. And at time. this like O'Connell I'm turn to to over for questions further back showing I'd the Dan fairly closing no

Daniel O'Connell

successful for an us to this what period year today's ACUXXX and be to on exciting you joining call. push the and and for hopefully everyone, INTERCEPT-AD to later updating for the field and Thank we again look thank promising as is We you, trial. you, forward forward continue and

call. So much. our That very concludes you thank

Operator

now may concludes you disconnect. This --

Acumen Pharmaceuticals (ABOS) 16 Aug 222022 Q2 Earnings call transcript